| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5898801 | Diabetes Research and Clinical Practice | 2016 | 24 Pages |
Abstract
Sitagliptin treatment may cause temporary changes of the proportion of lymphocyte subpopulations in patients with DM2. The consequent deregulation of the immune system should be considered as a possible cause of the eventual side effects of long term DPP-IV inhibition.
Keywords
GIPT regulatory lymphocytesIFNgammaSGLT2DM2HbA1cTregGLP-1μMDPP-IVSDF-1mAbIL-4natural killerMonoclonal antibodystandard deviationinterleukin-4cluster of differentiationDiabetes mellitus type 2dipeptidyl peptidase-IVImmune cellsbody mass indexBMISubstance PGlycated hemoglobingastric inhibitory polypeptideInterferon gammaglucagon like peptide-1Gliptins
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Lucie Sromova, Petr Busek, Helena Posova, Jana Potockova, Pavel Skrha, Michal Andel, Aleksi Sedo,